Save Product
Product Details
Synonyms
CD22, SIGLEC2, BL-CAM, SIGLEC-2, Siglec2, SIGLEC2FLJ22814
Source
PE-Labeled Human Siglec-2, His Tag (SI2-HP2H5) is produced via conjugation of PE to Human Siglec-2, His Tag with a new generation site-specific technology under Star Staining labeling platform. Human Siglec-2, His Tag is expressed from human 293 cells (HEK293). It contains AA Asp 20 - Arg 687 (Accession # P20273-1).
Predicted N-terminus: Asp 20
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus.
Conjugate
PE
Excitation Wavelength: 488 nm / 561 nm
Emission Wavelength: 575 nm
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, 0.2% BSA, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Evaluation of CAR expression
FACS Analysis of Anti-Siglec-2 CAR Expression
5e5 of anti-CD22 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) PE-Labeled Human Siglec-2, His Tag (Cat. No. SI2-HP2H5) and negative control protein respectively (Fig. C and B), and non-transfected 293 cells were used as a control (Fig. A). PE signal was used to evaluate the binding activity (QC tested).
ProtocolFACS Analysis of Non-specific binding to PBMCs
5e5 of PBMCs were stained with PE-Labeled Human Siglec-2, His Tag (Cat. No. SI2-HP2H5) and anti-CD3 antibody, washed and then analyzed with FACS. FITC signal was used to evaluate the expression of CD3+ T cells in PBMCs, and PE signal was used to evaluate the non-specific binding activity to PBMCs (QC tested).
Protocol
Customer Reviews Writing Reviews
Background
Recent Advances
Drug Development Progress- English Name：
CD22
- Category：
- Approved Drugs：
2 Details
- Drugs in Clinical Trials：
73 Details
- Highest Development Stage：
Approved
Contact Us
Drug Candidate Licensing
